KR980000442A - Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (1) - Google Patents

Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (1) Download PDF

Info

Publication number
KR980000442A
KR980000442A KR1019960020514A KR19960020514A KR980000442A KR 980000442 A KR980000442 A KR 980000442A KR 1019960020514 A KR1019960020514 A KR 1019960020514A KR 19960020514 A KR19960020514 A KR 19960020514A KR 980000442 A KR980000442 A KR 980000442A
Authority
KR
South Korea
Prior art keywords
sustained
release
pellet
sulfate
terbutaline sulfate
Prior art date
Application number
KR1019960020514A
Other languages
Korean (ko)
Other versions
KR0185293B1 (en
Inventor
김현수
민병희
최윤환
조항범
민미홍
Original Assignee
김태훈
주식회사 유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김태훈, 주식회사 유한양행 filed Critical 김태훈
Priority to KR1019960020514A priority Critical patent/KR0185293B1/en
Publication of KR980000442A publication Critical patent/KR980000442A/en
Application granted granted Critical
Publication of KR0185293B1 publication Critical patent/KR0185293B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 불황성 담체에 터부탈린설페이트(Terbrtaline sulfate) 및 구아이페네신(Guaifenesin)이 산포된 펠렛(Pellet)에 수불용성 피막물질이 피복된 터부탈린설페이트-구아이페네신 서방성 복합펠렛(A)과 불활성 담체에 구아이페네신이 산포된 펠렛에 수불용성 피막물질이 피복된 구아이페네신 서방성 단일펠렛(B)이 1:0.5 내지 1:3의 중량비로 혼합된 터부탈린설페이트-구아이페네신 서방성 복합제제에 관한 것이다.The present invention is a pellet in which terbrtaline sulfate and guaifenesin are dispersed in a sterile carrier, and a terbutaline sulfate-guifenecin sustained-release composite pellet coated with a water-insoluble coating material ( Terbutalin sulfate-sphere mixed with A) and a guipene-sin sustained release single pellet (B) coated with a water-insoluble coating material on a pellet in which guapenesine is dispersed on an inert carrier in a weight ratio of 1: 0.5 to 1: 3. It relates to an iphenesin sustained release combination.

Description

터부탈린설페이트-구아이페네신 서방성 복합제제(1)Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (1)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (7)

불황성 담체에 터부탈린설페이트(Terbrtaline sulfate) 및 구아이페네신(Guaifenesin)이 산포된 펠렛(Pellet)에 수불용성 피막물질이 피복된 터부탈린설페이트-구아이페네신 서방성 복합펠렛(A)과 불활성 담체에 구아이페네신이 산포된 펠렛에 수불용성 피막물질이 피복된 구아이페네신 서방성 단일펠렛(B)이 1:0.5 내지 1:3의 중량비로 혼합된 터부탈린설페이트-구아이페네신 서방성 복합제제.Terbutaline sulfate-Guifenecine sustained-release composite pellet (A) coated with a water-insoluble coating material on pellets in which terbrtaline sulfate and guaifenesin were dispersed on a inert carrier Terbutalin sulfate-guifenecin, in which a guiphenesine sustained-release single pellet (B) coated with a water-insoluble coating material on a pellet in which guapenesine is dispersed on an inert carrier is mixed at a weight ratio of 1: 0.5 to 1: 3. Sustained release combinations. 제1항에 있어서, 상기 서방성 복합펠렛(A) 및상기 서방성 단일펠렛(B)에 함유되는 구아이페네신의 중량비가 1:0.5 내지 1:3임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.The method of claim 1, wherein the weight ratio of the sustained release composite pellet (A) and the sustained release single pellet (B) in the weight ratio of guipene is 1: 0.5 to 1: 3 terbutaline sulfate-Guiape Necine sustained release combination. 제1항에 있어서, 상기 불활성 담체가 넌퍼레일시드(nonpareil seed) 또는 슈가시드(suger seed)임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.The method of claim 1, wherein the inert carrier is nonpareil seed (supar seed) or suger seed (suger seed) characterized in that the terbutaline sulfate-guifenesin sustained release combination formulation. 제1항에 있어서, 상기 서방성 복합펠렛(A) 및 상기 서방성 단일펠렛(B)에 함유되는 수불용성 피막물질이에칠셀룰로오스, 히드로제네이티드카스터오일, 슈어릴리즈(Surelease , Colorcon사), 유드라짇 또는 이들의 혼합물중에서 선택된 것임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.According to claim 1, wherein the water-insoluble coating material contained in the sustained-release composite pellet (A) and the sustained-release single pellet (B) is ethyl cellulose, hydrogenated castor oil, Surelease (Surelease) , Colorcon), Eudrapon or mixtures thereof. Terbutaline sulfate-guifenesine sustained-release complex preparations. 제4항에 있어서, 상기 수불용성 피막물질이 서방성 복합펠렛(A) 또는 서방성 단일펠렛(B)의 총중량에 대하여 3~30중량%임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.The method of claim 4, wherein the water-insoluble coating material is 3 to 30% by weight based on the total weight of the sustained-release composite pellet (A) or a sustained-release single pellet (B) terbutaline sulfate-guapenesine sustained release Combinations. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 터부탈린설페이트-구아이페네신 서방성 복합제제를 경질캅셀에 충전한 것을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합칼셀제.6. A terbutaline sulfate-guifenesine sustained-release complexed calcined agent according to any one of claims 1 to 5, wherein a hard capsule is filled with the terbutaline sulfate-guifenesine sustained release complex preparation. . 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 터부탈린설페이트-구아이페네신 서방성 복합제제를 타정한 것을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합정제(Spacetab).The sustained-release complex tablet of terbutaline sulfate-guiphenesine according to any one of claims 1 to 5, characterized in that the tablet is a tablet for terbutaline sulfate-guifenecin sustained release. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960020514A 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(1) KR0185293B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019960020514A KR0185293B1 (en) 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(1)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019960020514A KR0185293B1 (en) 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(1)

Publications (2)

Publication Number Publication Date
KR980000442A true KR980000442A (en) 1998-03-30
KR0185293B1 KR0185293B1 (en) 1999-05-01

Family

ID=19461229

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960020514A KR0185293B1 (en) 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(1)

Country Status (1)

Country Link
KR (1) KR0185293B1 (en)

Also Published As

Publication number Publication date
KR0185293B1 (en) 1999-05-01

Similar Documents

Publication Publication Date Title
AU665733B2 (en) Delayed, sustained-release pharmaceutical preparation
FR2714670B1 (en) New polypeptide ligand, its preparation, pharmaceutical composition containing it, and its application to the production of thrombopoietin.
NO895112D0 (en) COSMETIC MIXING.
NO175240C (en) Process for the preparation of a slow-release pharmaceutical composition comprising secondary granules
NO306539B1 (en) Drug-bearing particle and pharmaceutical mixture
CA2016039A1 (en) Extended release pharmaceutical formulations
KR890009380A (en) Sustained-release pharmaceuticals
CA1265449C (en) Devices for the controlled release of active substances, as well as process for the preparation thereof
KR900015734A (en) Osmotic continuous release oral delivery system containing a pharmaceutically acceptable active ingredient with improved core membrane adsorption properties
KR880000090A (en) Method for preparing sustained release ibuprofen formulation
SE8300577D0 (en) COVERAGE PROVIDING REGULATED DELIVERY OF ACTIVE INGREDIENTS FROM BIOLOGICALLY ACTIVE MIXTURES, IN PARTICULAR PHARMACEUTICAL PREPARATIONS, AS WELL AS TO MAKE BIOLOGICALLY ACTIVE MIXTURES WITH REGULATED ....
BR9907908A (en) Immediate-release microgranules, process for preparing them, and pharmaceutical preparations
ATE16394T1 (en) STABLE SALTS OF S-ADENOSINYLMETHIONINE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES AS THE ACTIVE SUBSTANCE.
GEP20022629B (en) Sustained-Release Microgranules Containing Diltiazem As The Active Principle and Gelatinous Capsule Containing the Same
KR980000442A (en) Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (1)
KR980000443A (en) Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (2)
JPH0688901B2 (en) Liquid long-term release pharmaceutical composition containing ionic drug
KR870010082A (en) Guar powder
KR910016321A (en) Granular pharmaceutical composition with long action time
ATE89168T1 (en) PHARMACEUTICAL LAXING AGENT.
JPS5282715A (en) Long acting drug composition
JPH03193733A (en) Sustained release preparation of theopylline
KR940008415B1 (en) Coating membrane and compositions prepared therefrom
JP3264722B2 (en) Capsule preparation
KR960006922A (en) Terpenadine-containing Pellet Compositions

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030204

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee